These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 25831837

  • 1. [Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
    Tsukasaki K.
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():632-5. PubMed ID: 25831837
    [No Abstract] [Full Text] [Related]

  • 2. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
    Marchand T, Revest M, Tattevin P, Chevrier S, Poullot E, Lamy T, Houot R.
    Leuk Lymphoma; 2013 Mar; 54(3):643-5. PubMed ID: 22924391
    [No Abstract] [Full Text] [Related]

  • 3. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
    Herold T, Seiler T, Egensperger R, Trumm C, Bergmann M, Franke D, Mumm FF, Schinwald N, Buske C, Dreyling M.
    Leuk Lymphoma; 2012 Jan; 53(1):169-72. PubMed ID: 21812535
    [No Abstract] [Full Text] [Related]

  • 4. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
    Gozzetti A, Candi V, Fabbri A, Schiattone L, Cencini E, Lauria F, Frasconi A, Crupi R, Raspadori D, Papini G, Defina M, Bartalucci G, Bocchia M.
    Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
    [Abstract] [Full Text] [Related]

  • 5. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T, Lech-Maranda E, Robak P.
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [Abstract] [Full Text] [Related]

  • 6. Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
    Molica S.
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1333-40. PubMed ID: 21929307
    [Abstract] [Full Text] [Related]

  • 7. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
    Norin S, Björkstrand B, Rommel F, Timberg L, Andersson PO, Häggström J, Aldrin A, Hansson L.
    Leuk Res; 2015 Jan; 39(1):33-7. PubMed ID: 25499233
    [Abstract] [Full Text] [Related]

  • 8. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
    Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group.
    Lancet; 2010 Oct 02; 376(9747):1164-74. PubMed ID: 20888994
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A, Israeli CLL Study Group.
    Haematologica; 2015 May 02; 100(5):662-9. PubMed ID: 25661442
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Fang C, Xu W, Xu M, Hong M, Zhu DX, Zhu HY, Wu YJ, Fan L, Qiao C, Zhuang Y, Miao KR, Liu P, Li JY.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan 02; 32(1):3-7. PubMed ID: 21429392
    [Abstract] [Full Text] [Related]

  • 11. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C, NCRI CLL Sub-Group.
    Br J Haematol; 2011 Mar 02; 152(5):570-8. PubMed ID: 21231927
    [Abstract] [Full Text] [Related]

  • 12. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
    Gruber M, Fleiss K, Porpaczy E, Skrabs C, Hauswirth AW, Gaiger A, Vanura K, Heintel D, Shehata M, Einberger C, Thalhammer R, Fonatsch C, Jäger U.
    Ann Hematol; 2011 Oct 02; 90(10):1131-6. PubMed ID: 21617923
    [Abstract] [Full Text] [Related]

  • 13. [Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
    Ettahar N, Legout L, Ajana F, Patoz P, Massongo M, Rose C, Senneville E.
    J Mycol Med; 2013 Mar 02; 23(1):57-63. PubMed ID: 23375857
    [Abstract] [Full Text] [Related]

  • 14. Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
    Sarid N, Eshel R, Rothman R, Shpringer M, Perry C, Solar I, Dezorella N, Gepstein L, Canaani J, Naparstek E, Polliack A, Herishanu Y.
    Eur J Haematol; 2012 Nov 02; 89(5):430-1. PubMed ID: 22816611
    [No Abstract] [Full Text] [Related]

  • 15. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
    Castiglioni MG, Scatena P, Pandolfo C, Mechelli S, Bianchi M.
    Leuk Lymphoma; 2006 Sep 02; 47(9):1985-6. PubMed ID: 17065021
    [No Abstract] [Full Text] [Related]

  • 16. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
    Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC, LUCID trial investigators.
    Br J Haematol; 2014 Nov 02; 167(4):466-77. PubMed ID: 25130401
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ, Xu W, Qian SX, Wu YJ, Hong M, Chen LJ, Wu HX, Lu H, Qiu HX, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug 02; 16(4):938-42. PubMed ID: 18718095
    [Abstract] [Full Text] [Related]

  • 18. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Tam C, Seymour JF, Brown M, Campbell P, Scarlett J, Underhill C, Ritchie D, Bond R, Grigg AP.
    Haematologica; 2005 May 02; 90(5):700-2. PubMed ID: 15921393
    [Abstract] [Full Text] [Related]

  • 19. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
    Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M.
    Blood; 2012 Mar 29; 119(13):3184-5. PubMed ID: 22461474
    [No Abstract] [Full Text] [Related]

  • 20. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
    Casak SJ, Lemery SJ, Shen YL, Rothmann MD, Khandelwal A, Zhao H, Davis G, Jarral V, Keegan P, Pazdur R.
    Oncologist; 2011 Mar 29; 16(1):97-104. PubMed ID: 21212432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.